United-Guardian, Inc. (UG)

Over the past six months, United-Guardian's stock price has remained largely stable. In Q3 2025, the company's shares declined by 10% following the earnings report, which showed a 26% drop in net sales and a 68% decrease in net income. The company declared a cash dividend of $0.25 per share in January 2026, marking its 31st consecutive year of dividend payments. Despite the decline in Q3 2025 earnings and revenue, the company maintains a strong gross profit margin and a healthy current ratio, but its Return on Capital Employed (ROCE) has shown a noticeable drop over the past five years.

Information regarding the specific demand seasonality for United-Guardian, Inc.'s products and services is not explicitly available. The company operates in markets that may have varying demand patterns. A decline in Q3 2025 cosmetic ingredients sales was noted, but without further context on typical seasonal trends.

United-Guardian, Inc. (UG) is involved in the research, development, manufacturing, and marketing of specialized products within the Consumer Defensive sector, including Household & Personal Products, Personal Products, and Specialty Chemicals. Founded in 1942, it holds over 30 patents. Its major product categories include cosmetic ingredients featuring the LUBRAJEL® line, FDA-approved pharmaceuticals like RENACIDIN®, medical lubricants under the Lubrajel brand, sexual wellness ingredients, and proprietary industrial products.

United-Guardian, Inc. develops, manufactures, sells, and markets its products in the United States and internationally. Key revenue is derived from sales made in the U.S. The company has expanded its distribution agreements, including with Brenntag Specialties for sexual wellness ingredients in the United States and several international markets, and with Azelis Group in Europe, with South Korea being added as a territory for another distributor.

United-Guardian's brand reputation has faced challenges, as reflected in market performance and analyst sentiment. The company's stock underperformed the US Personal Products industry and the broader US Market. It has received a consensus "Sell" rating from analysts and a low MarketRank™ score. However, the company is pursuing initiatives such as new distribution agreements, product development, and a new marketing strategy for Renacidin®, and its history of innovation contributes to its reputation.

United-Guardian, Inc. has a diverse ownership structure comprising institutional, retail, and individual investors. Approximately 23.16% of the stock is owned by institutional investors, with major holders including Renaissance Technologies LLC and Gamco Investors INC. ET AL. Individual investors, including insiders, and public companies own a significant portion of the stock, with approximately 80.13% held by public companies and individual investors, and 6.88% by insiders. Mr. Kenneth H. Globus, Chairman of the Board, holds 1.32 million shares.